Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 13 Jun 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Avelumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary) ; Propranolol (Primary)
Indications Bladder cancer; Carcinoma; Pelvic cancer; Renal cancer; Ureteral neoplasms; Urethral cancer; Urogenital cancer
Focus Adverse reactions

07 Jun 2024 Planned End Date changed from 1 Jan 2025 to 1 Jan 2027.
07 Jun 2024 Planned primary completion date changed from 1 Jan 2024 to 1 Jan 2026.
24 Jul 2023 Interventional Study Model changed to Parallel, Planned patient number hanged to 24, Avelumab and Nivolumab has been added in this study, hence number of treatment arms changed to 2, Primary endpoint has been amended and trial focus has been changed to Ar.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com